FDA
-
-
-
-
-
-
-
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
-
-
-
-
-
-
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
-
-
-
-
-
-
-
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
-
-
-
-
-
-
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American Coll
-
-
-
-
-
-
-
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
-
323,119 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

